Sean P. Pinney, MD, was recently named the first Director of Heart Failure and Transplantation for the Mount Sinai Health System. He will also continue to serve as Director of Advanced Heart Failure and Transplantation at The Mount Sinai Hospital and Associate Professor of Medicine (Cardiology) at Icahn School of Medicine at Mount Sinai, where he has led a number of clinical trials in heart failure, cardiac transplantation, and mechanical circulatory support. Read more
Mount Sinai scientists and clinicians are making notable advances in the study and treatment of heart failure, a common condition that occurs when the heart becomes too weak to pump and circulate enough blood through the body. Diseases that damage the heart—such as coronary artery disease, high blood pressure, and diabetes—can lead to heart failure, which develops over time as the heart’s pumping action grows weaker. It impacts an estimated 5 million adults and children in this country. Read more
Sean Pinney, MD, is Director of the Advanced Heart Failure and Transplantation Program at The Mount Sinai Hospital. He shared his answers to some of the most frequently asked questions of heart failure patients.
1. My health practitioner thinks I may have heart failure. Why did my health practitioner order so many different tests? Read more
The Mount Sinai Hospital is one of three institutions in New York State, and one of one hundred in the nation, selected to study the safety and effectiveness of an implantable cranial nerve stimulation device for heart failure patients with debilitating fatigue, shortness of breath, and heart arrhythmias.
Roger J. Hajjar, MD, a pioneering Mount Sinai researcher who has published cutting-edge studies on heart failure, has been named the recipient of the 2013 BCVS Distinguished Achievement Award by the American Heart Association and the Council on Basic Cardiovascular Sciences. Dr. Hajjar, who is The Arthur and Janet C. Ross Professor of Medicine and Director of The Helmsley Trust Translational Research Center, will be honored at the American Heart Association’s Scientific Sessions Annual Conference later this year.
“Dr. Hajjar will receive the award for his groundbreaking contributions to developing gene therapy treatments for cardiac disease,” says Joshua Hare, MD, who is President-elect of the Council on Basic Cardiovascular Sciences. He will also be recognized for his work on behalf of the Council.